Flashnote 25 February 2019

Malaysia

EQUITIES

SCGB MK Price (at 08:50, 25 Feb 2019 GMT)		Neutral RM1.75
Valuation - PER	RM	1.12-1.69
12-month target	RM	1.40
Upside/Downside	%	-20.0
12-month TSR	%	-16.0
Volatility Index		Medium
GICS sector	Ca	pital Goods
Market cap	RMm	2,263
Market cap	US\$m	555
Free float	%	26
30-day avg turnover	US\$m	0.6
Number shares on issue	m	1,293

Investment fundamentals

Year end 31 Dec		2017A	2018E	2019E	2020E
Revenue	m	2,076.3	2,162.2	2,309.1	1,879.7
EBITDA	m	202.4	217.8	234.7	201.1
EBIT	m	164.6	174.2	184.3	147.1
Reported profit	m	137.8	146.7	155.7	126.7
Adjusted profit	m	137.8	146.7	155.7	126.7
EPS rep	sen	10.7	11.3	12.0	9.8
EPS rep growth	%	11.9	6.5	6.1	-18.7
EPS adj	sen	10.7	11.3	12.0	9.8
EPS adj growth	%	11.9	6.5	6.1	-18.7
PER rep	Х	16.4	15.4	14.5	17.9
PER adj	Х	16.4	15.4	14.5	17.9
Total DPS	sen	7.0	7.0	7.0	7.0
Total div yield	%	4.0	4.0	4.0	4.0
ROA	%	9.5	9.3	9.8	7.9
ROE	%	26.3	25.2	24.3	18.3
EV/EBITDA	х	9.2	8.6	8.1	9.4
Net debt/equity	%	-63.5	-64.1	-54.3	-62.9
P/BV	Х	4.1	3.7	3.4	3.2

SCGB MK rel KLCl performance, & rec history



Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, February 2019 (all figures in MYR unless noted)

Macquarie Governance and Risk Score (MGRS)

On our proprietary <u>Governance and Risk Score</u> Sunway Construction Group scores in the third quartile of our current universe coverage.

Analysts

Macquarie Capital Securities (Malaysia) Sdn. Bhd.



Aiman Mohamad +60 3 2059 8986 aiman.mohamad@macquarie.com

Sunway Construction Group (SCGB MK) Results in-line, precast losses widened

Event

• Sunway Construction (SunCon) reported its FY18 results with adj. PAT of RM145mn (+7% YoY) tracking in-line with both MQ and consensus FY18 estimates at 99%. FY18 revenue registered at RM2.3bn (+9% YoY) tracking in-line with MQ and consensus estimates at 104% and 98%, respectively. Operational improvement is evidenced by an EBIT of RM175mn (+6% YoY) tracking in-line with MQ and consensus estimates at 100% and 96%, respectively. SunCon's construction division posted a PBT of RM182mn (+29% YoY); meanwhile its precast division's losses in 2H18 have dragged the division's PBT to only RM1mn (-96% YoY).

Impact

- RM1.6bn order wins recorded in FY18. SunCon managed to surpass its internal order win target of RM1.5bn in FY18 by securing a total order wins of RM1.6bn. While this was largely (80%) supported by the Sunway Berhad jobs, these order wins are imperative to ensure earnings growth for SunCon going ahead, especially with the slowdown in the sector and the uncertainty it faces in the LRT3 project as the corporate has yet to receive a green light from the project managers (MRCB and George Kent) to re-commence the construction of the project. In FY19E, SunCon is eyeing to secure up to RM1.5bn new orders with RM781mn already in the bag following the TNB headquarters project, secured last week.
- We flagged our concerns that the precast division's losses could widen in 4Q18. In our recent note on SunCon's outlook, we flagged our concerns that the precast division could continue seeing losses in 4Q18 and that this could even spill over to FY19E. In 4Q18 the division recorded another loss before tax of RM2.9mn, bringing down the FY18 division PBT to RM1mn. Strong competition in the Singapore precast market has reduced the division's turnover and margins. Going ahead, we believe the margins will continue to be suppressed as slower rollouts of HDB projects in 2019 is likely to continue given the slowdown in the Singapore property market.

SunCon results summary

RM 'mil	Macquarie FY18E Ests.	FY18 Actual	% of MQ forecast	Consensus FY18E Ests.	FY18 Actual	% of Consensus forecast
Revenue	2,162.2	2,256.8	104%	2,315.1	2,256.8	97%
EBIT	174.2	174.6	100%	182.8	174.6	95%
Profit before tax	185.8	183.1	99%	187.1	183.1	98%
Adjusted net profit	146.7	144.7	99%	146.6	144.7	99%

Source: Bloomberg, Company data, Macquarie Research, February 2019

Action and recommendation

Maintain Neutral on SunCon. Our top picks in 2019 are Gabungan AQRS
(AQRS MK, RM1.15, Outperform, TP: RM1.70), HSS Engineers (HSS MK,
RM1.11, Outperform, TP: RM1.30) and Kerjaya Prospek (KPG MK, RM1.32,
Outperform, TP: RM1.60).

Important disclosures:

Recommendation definitions

Macquarie – Asia, USA, Canada, Europe and Mazi Macquarie (SA):

Outperform – expected return >10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

Macquarie - Australia/New Zealand

Outperform – expected return >10% Neutral – expected return from 0% to 10% Underperform – expected return <0%

Note: expected return is reflective of a Medium Volatility stock and should be assumed to adjust proportionately with volatility risk

Volatility index definition*

This is calculated from the volatility of historical price movements.

Very high-highest risk – Stock should be expected to move up or down 60–100% in a year – investors should be aware this stock is highly speculative.

High – stock should be expected to move up or down at least 40–60% in a year – investors should be aware this stock could be speculative.

Medium – stock should be expected to move up or down at least 30–40% in a year.

Low-medium – stock should be expected to move up or down at least 25–30% in a year.

Low – stock should be expected to move up or down at least 15–25% in a year.

* Applicable to select stocks in Asia/Australia/NZ/Canada

Recommendations – 12 months

Note: Quant recommendations may differ from Fundamental Analyst recommendations

Financial definitions

All "Adjusted" data items have had the following adjustments made:

Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests

EPS = adjusted net profit / efpowa*

ROA = adjusted ebit / average total assets ROA Banks/Insurance = adjusted net profit /average

total assets

ROE = adjusted net profit / average shareholders funds Gross cashflow = adjusted net profit + depreciation *equivalent fully paid ordinary weighted average number of shares

All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).

Recommendation proportions - For quarter ending 31 December 2018

	AU/NZ	Asia	RSA	USA	CA	EUR
Outperform	53.56%	57.51%	47.06%	48.65%	69.08%	51.23%
Neutral	31.09%	30.24%	34.12%	46.22%	26.32%	39.41%
Underperform	15.36%	12.25%	18.82%	5.14%	4.61%	9.36%

(for global coverage by Macquarie, 4.12% of stocks followed are investment banking clients) (for global coverage by Macquarie, 1.92% of stocks followed are investment banking clients) (for global coverage by Macquarie, 0.47% of stocks followed are investment banking clients)

SCGB MK vs KLCI, & rec history



(all figures in MYR currency unless noted)

AQRS MK vs KLCI, & rec history Price Target AQRS KLCI 1900.00 3.00 1850.00 2.00 1750.00 1.50 1700.00 1.00 1650.00 Apr-17 Dec-17 Feb-19

(all figures in MYR currency unless noted)



(all figures in MYR currency unless noted)

KPG MK vs KLCI, & rec history



(all figures in MYR currency unless noted)

Note: Recommendation timeline – if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, February 2019

12-month target price methodology

SCGB MK: RM1.40 based on a PER methodology

AQRS MK: RM1.70 based on a Sum of Parts methodology

HSS MK: RM1.30 based on a PER methodology

KPG MK: RM1.60 based on a Sum of Parts methodology

Company-specific disclosures:

SCGB MK: Macquarie may be an Issuer of Structured Warrants on securities mentioned in this report AQRS MK: Macquarie may be an Issuer of Structured Warrants on securities mentioned in this report.

Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures.

Date	Stock Code (BBG code)	Recommendation	Target Price
11-Jan-2019	SCGB MK	Neutral	RM1.40
20-Jul-2018	SCGB MK	Neutral	RM2.00
19-Apr-2018	SCGB MK	Outperform	RM2.60
06-Oct-2017	SCGB MK	Outperform	RM2.80
26-Apr-2017	SCGB MK	Outperform	RM2.50

25 February 2019 2

 03-Sep-2016
 SCGB MK
 Outperform
 RM1.90

 11-Mar-2016
 SCGB MK
 Outperform
 RM1.67

Target price risk disclosures:

SCGB MK: Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures.

AQRS MK: Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures.

HSS MK: Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures.

KPG MK: Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures.

Analyst certification:

We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The Analysts responsible for preparing this report receive compensation from Macquarie that is based upon various factors including Macquarie Group Ltd total revenues, a portion of which are generated by Macquarie Group's Investment Banking activities.

General disclaimers:

Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital Markets Canada Ltd; Macquarie Capital Markets North America Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Limited, Taiwan Securities Branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Mazi Macquarie Securities (RF) (Pty) Ltd; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FCA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Macquarie salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions which are contrary to the opinions expressed in this research. Macquarie Research produces a variety of research products including, but not limited to, fundamental analysis, macro-economic analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise. The date and timestamp for above share price and market cap is the closed price of the price date. #CLOSE is the final price at which the security is traded in the relevant exchange on the date indicated. Members of the Macro Strategy team are Sales & Trading personnel who provide desk commentary that is not a product of the Macquarie Research department or subject to FINRA Rule 2241 or any other regulation regarding independence in the provision of equity research.

Country-specific disclaimers:

Australia: În Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organization of the Australian Securities Exchange. Macquarie Securities (Australia) Limited staff involved with the preparation of research have regular interaction with companies they cover. Additionally, Macquarie Group Limited does and seeks to do business with companies covered by Macquarie Research. There are robust information barriers in place to protect the independence of Macquarie Research's product. However, recipients of Macquarie Research should be aware of this potential conflict of interest. New Zealand: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. Canada: In Canada, research is prepared, approved and distributed by Macquarie Capital Markets Canada Ltd., a (i) member of the Investment Industry Regulatory Organization of Canada and the Canadian Investor Protection Fund, and (ii) participating organization of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. This research is distributed in the United States, as third party research by Macquarie Capital Markets North America Ltd., which is a registered broker-dealer and member of Financial Industry Regulatory Authority and the Securities Investor Protection Corporation. Macquarie Capital Markets North America Ltd. accepts responsibility for the contents of reports issued by Macquarie Capital Markets Canada Ltd. in the United States and sent to US persons. Any US person wishing to effect transactions in the securities described in the reports issued by Macquarie Capital Markets Canada Ltd. should do so with Macquarie Capital Markets North America Ltd. This research is intended for distribution in the United States only to major Institutional Investors (as such term is defined in SEC 15a-6 and Section 15 of the Securities Exchange Act of 1934, as amended) and is not intended for the use of any person or entity that is not a major institutional investor. Research analysts of Macquarie Capital Markets Canada Ltd. are not registered/qualified as research analysts with FINRA. The Research Distribution Policy of Macquarie Capital Markets Canada Ltd. is to allow all clients that are entitled to have equal access to our research. United Kingdom: In the United Kingdom, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 193905). Germany: In Germany, this research is issued and/or distributed by Macquarie Capital (Europe) Limited, Niederlassung Deutschland, which is authorised and regulated by the UK Financial Conduct Authority (No. 193905). and in Germany by BaFin. France: In France, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (No. 193905). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Limited, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only

25 February 2019 3

engages in non-business operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Limited. Japan: In Japan, research is Issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the Tokyo Stock Exchange, Inc. and Osaka Exchange, Inc. (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association). India: In India, research is issued and distributed by Macquarie Capital Securities (India) Pvt. Ltd. (CIN: U65920MH1995PTC090696), 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, India, which is a SEBI registered Research Analyst having registration no. INH000000545. Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 463469-W) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. **Taiwan**: In Taiwan, research is issued and distributed by Macquarie Capital Limited, Taiwan Securities Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. The recipient of this report shall not engage in any activities which may give rise to potential conflicts of interest to the report. Research Associate(s) in this report who are registered as Clerks only assist in the preparation of research and are not engaged in writing the research. Macquarie may be in past one year or now being an Issuer of Structured Warrants on securities mentioned in this report. Thailand: In Thailand, research is produced, issued and distributed by Macquarie Securities (Thailand) Ltd. Macquarie Securities (Thailand) Ltd. is a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: http://www.thaiiod.com/en/publications.asp?type=4. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at http://dis.kofia.or.kr/websquare/index.jsp?w2xPath=/wq/fundMgr/DISFundMgrAnalystStut.xml&divisionId=MDIS03002001000000&serviceId=SDIS03002 001000. **South Africa**: In South Africa, research is issued and distributed by Mazi Macquarie Securities (RF) (Pty) Ltd, a member of the JSE Limited. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (Europe) Limited, Macquarie Capital Markets Canada Ltd, Mazi Macquarie Securities (RF) (Pty) Ltd and Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. United States: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc., accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc.'s affiliate's analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Information regarding futures is provided for reference purposes only and is not a solicitation for purchases or sales of futures. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Securities, 125 W.55th Street, New York, NY 10019.

© Macquarie Group

25 February 2019 4



Equities

Asia Research

Head of Equity Research

Jake Lynch (Asia – Head)	(852) 3922 3583
Hiroyuki Sakaida (Japan – Head)	(813) 3512 6695
Conrad Werner (ASEAN – Head)	(65) 6601 0182

Automobiles, Auto Parts

Janet Lewis (China, Japan) (813) 3512 7856 Allen Yuan (China) (8621) 2412 9009 James Hong (Korea) (822) 3705 8661 Amit Mishra (India) (9122) 6720 4084

Banks and Financials

Scott Russell (Asia) (852) 3922 3567 Dexter Hsu (China, Taiwan) (8862) 2734 7530 Keisuke Moriyama (Japan) (813) 3512 7476 Chan Hwang (Korea) (822) 3705 8643 Suresh Ganapathy (India) (9122) 6720 4078 (65) 6601 0182 Conrad Werner (Singapore) Jayden Vantarakis (Indonesia) (6221) 2598 8310 Anand Pathmakanthan (Malaysia) (603) 2059 8833 Gilbert Lopez (Philippines) (632) 857 0892 Peach Patharavanakul (Thailand) (662) 694 7753

Basic Materials, Commodities

David Ching (China, Hong Kong)	(852) 3922 1823
Harunobu Goroh (Japan)	(813) 3512 7886
Yasuhiro Nakada (Japan)	(813) 3512 7862
Anna Park (Korea)	(822) 3705 8669
Sumangal Nevatia (India)	(9122) 6720 4093
Jayden Vantarakis (Indonesia)	(6221) 2598 8310

Conglomerates

David Ng (China, Hong Kong) (852) 3922 1291 (632) 857 0892 Gilbert Lopez (Philippines) Conrad Werner (Singapore) (65) 6601 0182

Consumer, Gaming

Linda Huang (Asia) (852) 3922 4068 Terence Chang (China, Hong Kong) (852) 3922 3581 (852) 3922 3768 (813) 3512 7879 Sunny Chow (China, Hong Kong) Leon Rapp (Japan) Kwang Cho (Korea) (822) 3705 4953 Amit Sinha (India) (9122) 6720 4085 Robert Pranata (Indonesia) (6221) 2598 8366 Richardo Walujo (Indonesia) Denise Soon (Malaysia) (6221) 2598 8369 (603) 2059 8845 Karisa Magpayo (Philippines) (632) 857 0899 Chalinee Congmuang (Thailand) (662) 694 7993

Emerging Leaders

Jake Lynch (Asia) (852) 3922 3583 Corinne Jian (Greater China) (8862) 2734 7522 Marcus Yang (China) (8621) 2412 9087 Kwang Cho (Korea) (822) 3705 4953 Conrad Werner (ASEAN) (65) 6601 0182 Bo Denworalak (Thailand) (662) 694 7774

Infrastructure, Industrials, Transportation

(8621) 2412 9082 (852) 3922 4749 Patrick Dai (China) Eric Zong (China, Hong Kong) Kunio Sakaida (Japan) (813) 3512 7873 James Hong (Korea) (822) 3705 8661 (8862) 2734 7522 (9122) 6720 4087 Corinne Jian (Taiwan) Inderjeetsingh Bhatia (India)

Internet, Media and Software

(852) 3922 3378 Wendy Huang (Asia) John Wang (China, Hong Kong) (852) 3922 3578 Ellie Jiang (China, Hong Kong) (852) 3922 4110 Frank Chen (China, Hong Kong) (852) 3922 1433 Andv Kim (Korea) (822) 3705 8690 Alankar Garude (India) (9122) 6720 4134

Oil, Gas and Petrochemicals

Aditya Suresh (Asia) (852) 3922 1265 Anna Park (Asia) (822) 3705 8669 Yasuhiro Nakada (Japan) (813) 3512 7862 Corinne Jian (Taiwan) (8862) 2734 7522 Ben Shane Lim (Malaysia) (603) 2059 8868 Yupapan Polpornprasert (Thailand) (662) 694 7729

Pharmaceuticals and Healthcare

David Ng (China, Hong Kong) (852) 3922 1291 Xiang Gao (China, Hong Kong) (8621) 2412 9006 Corinne Jian (China) (8862) 2734 7522 Mi Hyun Kim (Korea) (822) 3705 8689 Alankar Garude (India) (9122) 6720 4134 Richardo Walujo (Indonesia) (6221) 259 88 369

Property, REIT

David Ng (China, Hong Kong) (852) 3922 1291 Kelvin Tam (China) (852) 3922 1181 Nicholas Ting (Hong Kong) (852) 3922 1398 Keisuke Moriyama (Japan) Derrick Heng (Singapore) (813) 3512 7476 (65) 6601 0436 Abhishek Bhandari (India) (9122) 6720 4088 Richard Danusaputra (Indonesia) (6221) 2598 8368 Aiman Mohamad (Malaysia) (603) 2059 8986 Kervin Sisayan (Philippines) (632) 857 0893 (662) 694 7774 Bo Denworalak (Thailand)

Technology

Damian Thong (Asia, Japan) (813) 3512 7877 Jeffrey Ohlweiler (Greater China) (8862) 2734 7512 (8862) 2734 7523 Kavlin Tsai (Greater China) (8862) 2734 7534 Lynn Luo (Greater China) Patrick Liao (Greater China) (8862) 2734 7515 Verena Jeng (Greater China) (852) 3922 3766 Jin Guo (Greater China) (8621) 2412 9054 Daniel Kim (Korea) (822) 3705 8641 Abhishek Bhandari (India) (9122) 6720 4088

Telecoms

Prem Jearajasingam (ASEAN) (603) 2059 8989 Nathania Nurhalim (Indonesia) (6221) 2598 8365 Kervin Sisayan (Philippines) (632) 857 0893

Utilities, Renewables

Hiroyuki Sakaida (Japan) (813) 3512 6695 Patrick Dai (China) (8621) 2412 9082 Inderjeetsingh Bhatia (India) (9122) 6720 4087 Karisa Magpayo (Philippines) (632) 857 0899

Strategy, Country

Viktor Shvets (Asia, Global) (852) 3922 3883 David Ng (China, Hong Kong) (852) 3922 1291 Hiroyuki Sakaida (Japan) (813) 3512 6695 Chan Hwang (Korea) (822) 3705 8643 Jeffrey Ohlweiler (Taiwan) (8862) 2734 7512 Inderjeetsingh Bhatia (India) (9122) 6720 4087 Conrad Werner (ASEAN, Singapore) (65) 6601 0182 Jayden Vantarakis (Indonesia) (6221) 2598 8310 Anand Pathmakanthan (Malaysia) (603) 2059 8833 Gilbert Lopez (Philippines) (632) 857 0892 Peach Patharavanakul (Thailand) (662) 694 7753

Find our research at

Macquarie: Thomson: www.macquarieresearch.com www.thomson.com/financial Reuters: www.knowledge.reuters.com Bloomberg: MAC GO

Factset: http://www.factset.com/home.aspx www.capitaliq.com CapitallQ

Email macresearch@macquarie.com for access

Asia Sales

Regional Heads of Sales

Miki Edelman (Global) (1 212) 231 6121 Amelia Mehta (Asia) (65) 6601 0211 Alan Chen (Asia) (852) 3922 2019 Sandeep Bhatia (India) (9122) 6720 4101 Tim Huang (Indonesia) (6221) 2598 8303 Thomas Renz (Geneva) (41 22) 818 7712 Tomohiro Takahashi (Japan) (813) 3512 7823 John Jay Lee (Korea) (822) 3705 9988 Nik Hadi (Malaysia) (603) 2059 8888 Gino C Rojas (Philippines) (632) 857 0861

Regional Heads of Sales cont'd

Paul Colaco (San Francisco) (1 415) 762 5003 Eric Lin (Taiwan) (8862) 2734 7590 Angus Kent (Tháiland) (662) 694 7601 Mothlib Miah (UK/Europe) (44 20) 3037 4893 (44 20) 3037 4873 Christina Lee (US)

Sales Trading

Mark Weekes (Asia) (852) 3922 2084 (6221) 515 1555 Stanley Dunda (Indonesia)

Sales Trading cont'd

Suhaida Samsudin (Malaysia) Michael Santos (Philippines) Chris Reale (New York) Marc Rosa (New York) Justin Morrison (Singapore) Brendan Rake (Thailand) Mike Keen (UK/Europe)

(603) 2059 8888 (632) 857 0813 (1 212) 231 2555 (1 212) 231 2555 (65) 6601 0288 (662) 694 7707 (44 20) 3037 4905